RxDoctor Payments Data

Abdulah Alrifai, MD

Cardiovascular Disease · Hazel Crest, ILNPI 1265774616

Payments from drug & device makers

$46,035in general payments, 2019–2025

Across 221 payments — averaging $208.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$19K
  • Inari Medical, Inc.$8K
  • Abbott$7K
  • Surmodics, Inc.$6K
  • Medtronic$2K
  • Edwards Lifesciences$1K
  • plus $3K from 24 others

What the payments were for

  • Consulting fees$3,1507%
  • Speaking & faculty fees$21,05046%
  • Travel & lodging$11,44725%
  • Food & beverage$10,10422%
  • Education$2851%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,035 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$135,680
Medicare patients
463
Services billed
1,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$102,653
EntrestoSacubitril/Valsartan37$50,726
JardianceEmpagliflozin27$39,825
XareltoRivaroxaban16$25,039
Repatha SureclickEvolocumab16$11,322
Praluent PenAlirocumab13$6,140
Atorvastatin Calcium194$1,721
ClopidogrelClopidogrel Bisulfate140$1,721
Metoprolol Succinate102$1,549
Cilostazol34$1,144
Valsartan19$948
Carvedilol113$802
Amlodipine Besylate110$767
Hydralazine Hcl29$694
Losartan Potassium39$675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$24$50,72637 claims
Boehringer IngelheimJardiance$172$39,82527 claims
Johnson & JohnsonXarelto$179$25,03916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Hazel Crest

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →